Hyaluronic Acid Treatment
- In 1997, The US Food and Drug Administration (FDA), has approved intra-articular Hyaluronic Acid (HA) for knee osteoarthritis treatment.
- American College of Rheumatology (ACR) and the American Academy of Orthopaedic Surgeons (AAOS) has been added HA for OA treatment guidelines¹‚²
- There are over 60 clinical trials regarding efficacy and safety of HA treatment.
Indication of Reviscon
It is used in the treatment of pain and loss of flexibility as a result of degenerative and traumatic changes in any synovial joint (flexible joints; such as knees, hips, shoulders, elbows, finger and toes).
It is indicated in the cases that had inadequate response to non-pharmacological conservative therapy and simple analgesics. Treatment can be applied to more than one joint at the same time. Therapy course may be repeated when needed.
1 – Dieppe PA, Buckwalter JA. Management of limb joint osteoarthritis. Osteoarthritis and related disorders. In: Klippel JH, Dieppe PA. (Eds) Rheumatology, Second Edition. London: Mosby; 1998. p. 8.9.3.
2 – Neustadt DH. Intra-Articular injections for osteoarthritis of the knee. Cleve Clin J Med 2006;73:897-8, 901-4, 906-11.7.